SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-23-000203
Filing Date
2023-12-21
Accepted
2023-12-21 17:47:53
Documents
1
Period of Report
2023-12-20

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1703198862.html 4  
1 FORM 4 wk-form4_1703198862.xml 4 5415
  Complete submission text file 0001725160-23-000203.txt   7048
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Bunker Kevin D. (Reporting) CIK: 0001807484 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 231506643